Download PDF
Open Access
CC BY-NC-ND 4.0 · Journal of Diabetes and Endocrine Practice 2024; 07(01): 15-24
DOI: 10.1055/s-0043-1775966
Review Article

Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence

Authors

  • Rahaf Wardeh 

    1   Department of Internal Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates

  • Tabarak Haamid Elbo Iswadi 

    1   Department of Internal Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates

  • Hind Alsharayri

    1   Department of Internal Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates

  • Fauzia Rashid

    2   Department of Diabetes & Endocrinology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates

  • Nada Alhashemi

    2   Department of Diabetes & Endocrinology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates

  • Alaaeldin Bashier 

    2   Department of Diabetes & Endocrinology, Dubai Hospital, Dubai Health Authority, Dubai, United Arab Emirates

Funding and Sponsorship None.
Further Information
Also available at
  Permissions and Reprints

Abstract

Background Tirzepatide is a novel dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors agonist in management of type 2 diabetes mellitus. The aim of this literature review is to comprehensively assess its clinical, biochemical, and safety profiles.

Materials and Methods Search was conducted in several databases including PubMed from drug inception through end of 2022. Publications relevant to tirzepatide including randomized controlled trials, meta-analysis studies, post-hoc analyses, and conference proceedings were identified to examine its profile. Additional necessary references were explored and included as needed.

Results Tirzepatide is a twincretin, acting on both GLP-1 and GIP receptors. Its performance in glycemic control and weight loss was greater than that of GLP-1 receptor agonist or insulin, comparatively. It demonstrated promising positive renal outcomes and was not associated with a higher cardiovascular risk, in addition to favorable effects on lipid, hepatic and blood pressure profiles. Most common adverse events were gastrointestinal side effects and hypoglycemia.

Conclusion Novel dual GLP-1/GIP agonist Tirzepatide shows superior efficacy in glycemic control and weight loss in T2 diabetes mellitus patients. More evidence is needed to explore and compare long-term cardiovascular and renal outcomes reflecting real-world clinical practice.

Keywords

tirzepatide - GIP/GLP-1 agonist - type 2 diabetes - weight loss - glycemic control - incretin

Compliance with Ethical Principles

This review falls in compliance with research ethical standards and principles. There has been no human subjects or participants involved.


Authors' Contributions

A.B. conceived the concept of the study and coordinated its design. R.W., T.E., and H.A. performed the literature search, selection of studies and review of the data, drafting the manuscript and editing it. F.R., N.A., and A.B. critically reviewed the manuscript and edited it. R.W. and A.B. supervised the article. All authors read and approved the final manuscript.




Publication History

Article published online:
13 October 2023

© 2023. Gulf Association of Endocrinology and Diabetes (GAED). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India